Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Victory Capital Management Inc. cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 723,297 shares of the specialty pharmaceutical company’s stock after selling 24,974 shares during the quarter. Victory Capital Management Inc. owned 2.22% of Collegium Pharmaceutical worth $22,263,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. raised its stake in shares of Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after buying an additional 883,380 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after acquiring an additional 272,565 shares during the period. New York State Common Retirement Fund boosted its position in shares of Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock worth $6,190,000 after purchasing an additional 188,347 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Collegium Pharmaceutical by 713.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 111,394 shares during the period. Finally, Federated Hermes Inc. increased its holdings in shares of Collegium Pharmaceutical by 76.0% in the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock valued at $6,549,000 after purchasing an additional 91,911 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on COLL shares. Piper Sandler reissued an “overweight” rating and set a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Truist Financial raised their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $38.06 on Thursday. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. The business’s fifty day moving average price is $37.61 and its two-hundred day moving average price is $32.17. The stock has a market cap of $1.24 billion, a PE ratio of 32.25 and a beta of 1.06. Collegium Pharmaceutical, Inc. has a one year low of $20.83 and a one year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. The business had revenue of $149.75 million for the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.